| Identification | Back Directory | [Name]
CLK inhibitor T3
(T3) | [CAS]
2109805-56-1 | [Synonyms]
T3-CLK
CLK-IN-T3
CLK inhibitor T3
(T3)
Benzamide, 4-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-N-[6-(4-pyridinyl)imidazo[1,2-a]pyridin-2-yl]- | [Molecular Formula]
C28H30N6O2 | [MDL Number]
MFCD31689325 | [MOL File]
2109805-56-1.mol | [Molecular Weight]
482.58 |
| Chemical Properties | Back Directory | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: 2mg/mL, clear (warmed) | [form ]
Solid | [pka]
4.70±0.46(Predicted) | [color ]
Off-white to light yellow | [InChIKey]
IEFFSHLHNYVSEF-UHFFFAOYSA-N | [SMILES]
C(NC1=CN2C(=N1)C=CC(C1C=CN=CC=1)=C2)(=O)C1=CC=C(C(C)(C)C(N2CCN(C)CC2)=O)C=C1 |
| Hazard Information | Back Directory | [Uses]
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC50s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity[1]. | [Biological Activity]
T3-CLK (T3) is a cell permeablehighly potent and selective cell-base stable inhibitor of CDC-like kinase (CLK) th at exhibits dose-dependent alternative splicing effects in HCT116 colorectal cancer cells. T3-CLK increases conjoined gene (CG) transcription. | [IC 50]
CLK1: 0.67 nM (IC50); CLK2: 15 nM (IC50); CLK3: 110 nM (IC50); DYRK1A: 260 nM (IC50); DYRK1B: 230 nM (IC50) | [References]
[1] Funnell T, et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel smallmolecule inhibitor. Nat Commun. 2017 Feb 23;8(1):7. DOI:10.1038/s41467-016-0008-7 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|